



Pharmaceuticals Limited

**Registered & Corporate Office :**

Plot No. 72, H. No. 8-2-334/3 & 4, Road No. 5,  
Opp. SBI Executive Enclave, Banjara Hills,  
Hyderabad - 500 034, Telangana, INDIA.

Tel : +91-40-2525 9999, 3535 9999

Fax : +91-40-2525 9889

CIN : L24239TG1987PLC008066

Email: info@smspharma.com, www.smspharma.com

Date: 12<sup>th</sup> December, 2025

To  
The Manager,  
Corporate Filings Department,  
BSE Limited,  
Phiroze Jeejeebhoy Towers,  
Dalal Street,  
Mumbai- 400 001

**Security Code: 532815**

The Manager,  
Listing Compliance Department,  
National Stock Exchange of India Ltd.  
Exchange Plaza, Plot no. C/1, G Block,  
Bandra-Kurla Complex, Bandra (E), Mumbai  
- 400 051.

**Symbol: SMSPHARMA**

Dear Sir/Madam,

**Sub: Completion of USFDA inspection at Vizag manufacturing facility: Reg.**

Ref: Pursuant to Regulation 30 of the SEBI (LODR) Regulations, 2015.

We wish to inform you that, the United States Food and Drug Administration (USFDA) has conducted an inspection of the Company's Active Pharmaceutical Ingredient(API) manufacturing facility located at Visakhapatnam, Andhra Pradesh, please find the enclosed Company statement titled "**Successful completion of USFDA inspection at Vizag facility**"

The above information will also be made available on the website of the Company at [www.smspharma.com](http://www.smspharma.com)

This is for your information and records.

Thanking you

Yours Faithfully

**For SMS Pharmaceuticals Limited**

**Thirumalesh Tumma**  
**Company Secretary**



**December 12, 2025**

## **Successful completion of USFDA inspection at Vizag facility**

SMS Pharmaceuticals Limited (SMS Pharma) (NSE: SMSPHARMA; BSE:532815) is pleased to announce the successful completion of a US Food and Drug Administration (USFDA) inspection at its Active Pharmaceutical Ingredient (API) manufacturing facility situated at Visakhapatnam, Andhra Pradesh.

The inspection, conducted from December 08 to December 12, 2025, concluded with one minor observation in Form 483. The observation is procedural in nature and does not relate to data integrity. The Company will provide the necessary response to USFDA within the stipulated time period.

The Vizag facility is a 3,000 KL flagship, multipurpose API manufacturing facility, specialising in niche, large-volume molecules. It is backed by multiple global regulatory approvals, including USFDA, WHO-GMP, EU-GMP, KFDA, CDSCO, and PMDA.

**Commenting on this achievement, Mr. P. Vamsi Krishna, Executive Director, stated:**

*"The successful completion of the USFDA inspection reaffirms our commitment to stringent quality, compliance, and global regulatory standards. This marks the 4<sup>th</sup> inspection for this facility and the 12<sup>th</sup> across our manufacturing sites, including two audits of our Central Laboratory Analytical Services (CLAS). This milestone further reinforces our position as a reliable partner to global pharmaceutical companies and ensures continued, high-quality API supply to key international markets."*

### **About SMS Pharmaceuticals Limited**

Established in 1990, SMS Pharmaceuticals Limited is a diversified and integrated pharmaceutical company specialising in API and intermediates for global customers. The Company operates two state-of-the-art manufacturing facilities in Hyderabad and Vizag, with capacities of 120 KL and 3,000 KL, respectively. Supported by strong in-house R&D capabilities, the Company has a proven track record of delivering quality products across a diversified portfolio of therapeutic segments, serving as a trusted partner to a global customer base in over 75 countries.

**For any further information, please contact:**

<b>Company</b>	<b>Investor relations</b>
<b>SMS Pharmaceuticals Limited</b>	<b>Eqsponent Partners LLP</b>
Mr. Thirumalesh Tumma Email: <a href="mailto:complianceofficer@smspharma.com">complianceofficer@smspharma.com</a>	Mr. Aditya Dutta Email: <a href="mailto:smspharma.IR@eqsponent.com">smspharma.IR@eqsponent.com</a>

### **DISCLAIMER**

*Certain statements that are made in the Press Release may be forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties like significant changes in the economic environment in India and overseas, tax laws, inflation, litigation, etc. Actual results might differ substantially from those expressed or implied. SMS Pharmaceuticals Limited will not be in any way responsible for any action taken based on such statements and discussions; undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.*